Valneva SE (VALN) , a specialty vaccine company, has achieved a significant milestone with the approval of its single-dose chikungunya vaccine, IXCHIQ, by Health Canada. This approval follows the FDA's nod in November 2023 as well as the European Medicines Agency's recent recommendation for marketing authorization in Europe. Also known as CHIKV, Chikungunya is a mosquito-borne viral disease spread by the bites of infected female Aedes mosquitoes. It commonly causes fever, severe joint pain, muscle pain, hea ...